Research programme: serotonin 2C receptor agonists - Vernalis/Roche

Drug Profile

Research programme: serotonin 2C receptor agonists - Vernalis/Roche

Alternative Names: VER 3323; VER 5384; VER 5593

Latest Information Update: 16 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Class
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 03 Dec 2003 Roche has selected a development candidate from the research programme for obesity for preclinical studies
  • 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis
  • 27 Jun 2003 Vernalis plans to select a new development candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top